A Phase Ib Randomized, Double-blind, Placebo-controlled, Ascending Sequential Dose, Adaptive Design Study to Evaluate the Safety, Antiretroviral Activity, and Pharmacokinetics of Intravenous Deferiprone in Treatment-Naive HIV-Positive Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Deferiprone (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors ApoPharma
- 07 Jun 2017 Biomarkers information updated
- 03 Jun 2016 Status changed from active, no longer recruiting to completed.
- 09 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.